A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Serabelisib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 16 Feb 2017 Status changed from active, no longer recruiting to discontinued.
- 25 Jan 2017 This trial has been discontinued in Italy.
- 18 Jan 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.